Advertisement

Inpharma Weekly

, Volume 1289, Issue 1, pp 8–8 | Cite as

Targeted CMV prophylaxis with valganciclovir viable

Clinical study
  • 3 Downloads

Keywords

Valganciclovir Oral Valganciclovir Total Lifetime Cost Adjusted Life Expectancy Minor Adverse Reaction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 2001

Personalised recommendations